All In Biotech

Drug Trial Radar · NCT00264953

HD11 for Intermediate Stages

Last checked: Nov 20, 2026Latest source record: Aug 4, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,395

Actual

Start

May 1998

Primary completion

Jan 2003

Sponsor

Lead sponsor
University of CologneAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.

Conditions

  • Hodgkin´s Lymphoma

Interventions

  • AdriamycinDrug

  • BleomycinDrug

  • VinblastineDrug

  • DTICDrug

  • EtoposideDrug

  • ProcarbazineDrug

  • PrednisoneDrug

  • VincristineDrug

  • radiation therapyRadiation

    20 or 30Gy IF-RT

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.